Coherus Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CHRS and other ETFs, options, and stocks.About CHRS
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI.
CEODenny M. Lanfear
CEODenny M. Lanfear
Employees228
Employees228
HeadquartersRedwood City, California
HeadquartersRedwood City, California
Founded2010
Founded2010
Employees228
Employees228
CHRS Key Statistics
Market cap150.48M
Market cap150.48M
Price-Earnings ratio-0.78
Price-Earnings ratio-0.78
Dividend yield—
Dividend yield—
Average volume940.07K
Average volume940.07K
High today$1.25
High today$1.25
Low today$1.20
Low today$1.20
Open price$1.22
Open price$1.22
Volume831.08K
Volume831.08K
52 Week high$1.89
52 Week high$1.89
52 Week low$0.71
52 Week low$0.71
Stock Snapshot
With a market cap of 150.48M, Coherus Oncology(CHRS) trades at $1.23. The stock has a price-to-earnings ratio of -0.78.
On 2025-12-04, Coherus Oncology(CHRS) stock traded between a low of $1.20 and a high of $1.25. Shares are currently priced at $1.23, which is +2.5% above the low and -1.6% below the high.
The Coherus Oncology(CHRS)'s current trading volume is 831.08K, compared to an average daily volume of 940.07K.
During the past year, Coherus Oncology(CHRS) stock moved between $0.71 at its lowest and $1.89 at its peak.
During the past year, Coherus Oncology(CHRS) stock moved between $0.71 at its lowest and $1.89 at its peak.
People also own
Based on the portfolios of people who own CHRS. This list is generated using Robinhood data, and it’s not a recommendation.